Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 10/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | BCR | P11274 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL690230 | 0.88 | SRC (0.41) | SRCPRKCQABL1BCREGFR | |
| SCHEMBL691207 | 0.84 | FLT1 (0.45) | SRCMEN1ALDH1A1KMT2AKDM4E | |
| SCHEMBL13384743 | 0.79 | KCNQ3 (0.47) | SRCABL1BCREGFRERBB2 | |
| SCHEMBL690500 | 0.77 | LRRK2 (0.40) | SRCEGFRERBB2ALDH1A1SLC22A12 | |
| SCHEMBL24122932 | 0.75 | SLC22A12 (0.45) | SRCABL1BCREGFRMAP2K1 | |
| SCHEMBL30489823 | 0.75 | SLC22A12 (0.45) | SRCABL1BCREGFRMAP2K1 | |
| SCHEMBL10125083 | 0.72 | SRC (0.43) | SRCPRKCQABL1BCREGFR | |
| SCHEMBL21600850 | 0.70 | GAA (0.50) | SRCEGFRERBB2MAP2K1MEN1 | |
| SCHEMBL30379210 | 0.70 | GAA (0.50) | SRCEGFRERBB2MAP2K1MEN1 | |
| SCHEMBL4486546 | 0.69 | CYP11B2 (0.40) | ALDH1A1KDM4ETDP1VCAM1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9446034-B2 | Pyrazolylaminopyridines as inhibitors of FAK | GLAXOSMITHKLINE LLC (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160095841-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2016-04-07 | — | — | US | disclosed |
| US-20150265589-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2015-09-24 | — | — | US | disclosed |
| US-9012479-B2 | Pyrazolylaminopyridines as inhibitors of FAK | GLAXOSMITHKLINE LLC (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140155410-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140107131-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC (US) | 2014-04-17 | — | — | US | disclosed |
| EP-2421537-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GlaxoSmithKline LLC (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20110269774-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2011-11-03 | — | — | US | disclosed |
| US-20110207743-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2011-08-25 | — | — | US | disclosed |
| WO-2010062578-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC (US) | 2010-06-03 | — | — | WO | disclosed |
| US-20100113475-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269774-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | SRC 4/4885PRKCQ 220/4885ABL1 25/4885 |
| US-20160095841-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | SRC 4/4885PRKCQ 220/4885ABL1 25/4885 |
| US-20150265589-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | SRC 4/4885PRKCQ 220/4885ABL1 25/4885 |
| US-20100113475-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | SRC 4/4885PRKCQ 220/4885ABL1 25/4885 |
| US-20110207743-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | SRC 4/4885PRKCQ 220/4885ABL1 25/4885 |
| US-20140107131-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | SRC 4/4885PRKCQ 220/4885ABL1 25/4885 |
| US-20140155410-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | SRC 4/4885PRKCQ 220/4885ABL1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.